Clinical trials: Antibiotic Treatment
Helicobacter Pylori Eradication Antibiotic
Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection
This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg, Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID…
- Trial name
- NCT02835560
- Testing
- Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy, Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
- Volunteers
- 100 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Lung Infection
Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection
The purpose of this research study is to test the safety and effectiveness of inhaled Interferon gamma-1b (IFN-g 1b), when administered for 48 weeks and in combination with oral antibiotics which may be administered for up to 72…
- Trial name
- NCT00043355
- Testing
- interferon gamma-1b
- Volunteers
- 100 people
- Sponsor
- InterMune
Ocular Inflammation, Infection Associated Blepharitis
Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or…
- Conditions
- Ocular Inflammation, Infection Associated Blepharitis, Keratitis, Conjunctivitis, Bacterial
- Trial name
- NCT01721694
- Testing
- azithromycin 1.5% + Loteprednol 0,5% (separately)
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Pouchitis
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry.
- Trial name
- NCT00583531
- Testing
- AST-120
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ocera Therapeutics
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Infectious Diseases
BAY 0 9867 Cipro Pediatric Use Study (QUIP)
Objective and subjective musculoskeletal evaluations will be performed to determine differences in the ciprofloxacin versus non-quinolone treated pediatric patients so that we can tell what the natural occurrence of such…
- Trial name
- NCT00761462
- Testing
- Ciprofloxacin, Non-quinolone antibiotic
- Where
- 67 sites in United States, Canada
- Volunteers
- 1,029 people
- Sponsor
- Bayer
Sinusitis, Bacterial Infections
Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis
- Trial name
- NCT00493038
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin/Clavulanate
- Where
- 34 sites in Italy
- Volunteers
- 293 people
- Sponsor
- Bayer
Sepsis
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
- Trial name
- NCT00318552
- Testing
- Meropenem
- Where
- 12 sites in Hungary
- Volunteers
- 160 people
- Sponsor
- Pfizer
Prosthetic Joint Infection (PJI)
A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants
This is a Phase 2b, randomized, controlled, open-label clinical study evaluating the efficacy, safety, and local PK profiles of TNP-2092 administered via IA injection on a background of antibiotic treatment in participants with…
- Trial name
- NCT07858916
- Testing
- TNP-2092 for injection, Vancomycin Hydrochloride for Injection, Oral antibiotics
- Where
- China
- Volunteers
- 40 people
- Sponsor
- TenNor Therapeutics (Zhongshan) Limited
Bacterial Infections
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.
- Trial name
- NCT02527681
- Testing
- Ceftobiprole medocaril
- Where
- 14 sites in United States, Belgium and 4 more
- Volunteers
- 15 people
- Sponsor
- Basilea Pharmaceutica
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
Complicated Intra-abdominal Infection
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
- Trial name
- RECLAIM3 (NCT01726023)
- Testing
- Ceftazidime-avibactam, metronidazole, Meropenem
- Where
- 30 sites in China, South Korea and 1 more
- Volunteers
- 486 people
- Sponsor
- Pfizer
Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized…
- Trial name
- VITORA (NCT03944369)
- Testing
- KB109, No intervention
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Kaleido Biosciences
Infection, Pneumonia
A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)
The primary objective of this study is a comparison between MK0787B and standard therapy.
- Trial name
- NCT00445094
- Testing
- MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days, Comparator: amikacin / Duration of Treatment: 3 Days, Comparator: tazocin / Duration of Treatment: 3 Days
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Otitis Media Acute
Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children
A pragmatic, mixed-method trial is to show the ability of OtoSight to change management of the pediatric patient presenting with ear pain in a way that improves patient outcomes and reduces costs.
- Trial name
- OTO-MATIC (NCT06285812)
- Testing
- OtoSight Middle Ear Scope
- Where
- 7 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- PhotoniCare, Inc.
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the…
- Trial name
- NCT03233438
- Testing
- Dalbavancin, Usual Care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Allergan
Bacterial Conjunctivitis
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1%…
- Trial name
- NCT06911424
- Testing
- Fusidic Acid 1%
- Where
- 38 sites in United States
- Volunteers
- 400 people
- Sponsor
- Baxis Pharmaceuticals, Inc.
Peri-Implantitis, Plaque, Dental
Antibacterial Photodynamic Therapy in the Management of Peri-implantitis
This early-stage study is designed to determine the efficacy of the Lumoral method in periimplantitis. Improved supragingival plaque control can help to also sustain subgingival plaque management in the long term.
- Trial name
- NCT06017817
- Testing
- Lumoral Treatment, Standard oral hygiene instructions, Scaling and root planing (SRP
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Koite Health Oy
Community Acquired Pneumonia
Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
This study will compare the efficacy, safety and tolerability of EDP-420 versus another oral antibiotic in the treatment of community acquired pneumonia
- Trial name
- NCT00270517
- Testing
- EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Gram Positive Bacterial Infection
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected…
- Trial name
- NCT01019395
- Testing
- Daptomycin
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)